Eli Lilly and Company $LLY Shares Purchased by Pinnacle Wealth Management Advisory Group LLC

Pinnacle Wealth Management Advisory Group LLC raised its holdings in Eli Lilly and Company (NYSE:LLY) by 2.5% in the 2nd quarter, HoldingsChannel reports. The fund owned 3,777 shares of the company’s stock after acquiring an additional 93 shares during the period. Pinnacle Wealth Management Advisory Group LLC’s holdings in Eli Lilly and Company were worth $2,944,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in LLY. Midwest Trust Co purchased a new stake in shares of Eli Lilly and Company in the second quarter valued at $38,382,000. DJE Kapital AG boosted its stake in Eli Lilly and Company by 4.0% in the 2nd quarter. DJE Kapital AG now owns 121,967 shares of the company’s stock worth $94,471,000 after buying an additional 4,674 shares during the last quarter. Prescott Group Capital Management L.L.C. grew its holdings in Eli Lilly and Company by 9.3% in the 2nd quarter. Prescott Group Capital Management L.L.C. now owns 2,086 shares of the company’s stock valued at $1,626,000 after buying an additional 177 shares during the period. Acadian Asset Management LLC increased its stake in shares of Eli Lilly and Company by 150.3% during the 2nd quarter. Acadian Asset Management LLC now owns 190,596 shares of the company’s stock valued at $148,567,000 after acquiring an additional 114,441 shares during the last quarter. Finally, Brio Consultants LLC increased its stake in shares of Eli Lilly and Company by 28.4% during the 2nd quarter. Brio Consultants LLC now owns 371 shares of the company’s stock valued at $290,000 after acquiring an additional 82 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY opened at $923.35 on Friday. The business’s 50-day simple moving average is $799.97 and its 200 day simple moving average is $775.40. The company has a market cap of $872.92 billion, a P/E ratio of 60.35, a PEG ratio of 1.21 and a beta of 0.43. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a one year low of $623.78 and a one year high of $955.46.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. During the same quarter in the prior year, the business earned $1.18 EPS. Eli Lilly and Company’s quarterly revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be issued a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 29.35%.

Insider Activity

In other Eli Lilly and Company news, Director Gabrielle Sulzberger bought 117 shares of the company’s stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average cost of $641.18 per share, with a total value of $75,018.06. Following the completion of the transaction, the director owned 2,703 shares in the company, valued at $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director J Erik Fyrwald purchased 1,565 shares of the business’s stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the purchase, the director owned 74,578 shares of the company’s stock, valued at approximately $47,903,686.74. This represents a 2.14% increase in their position. The SEC filing for this purchase provides additional information. Over the last quarter, insiders bought 4,314 shares of company stock worth $2,766,929. Corporate insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

Several research firms recently issued reports on LLY. Cantor Fitzgerald raised their target price on shares of Eli Lilly and Company from $925.00 to $985.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. Daiwa America downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. Morgan Stanley decreased their price target on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a report on Friday, October 3rd. DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Finally, HSBC increased their target price on Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $960.88.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.